Table 2.

Model Estimates - Clinical Assumptions

Clinical Parameter	Estimate [refs]	Range
Probabilities
Surgical cytoreduction suboptimal	0.33a	0.00 – 1.00
Neuropathy | CP	0.07a	0.03 – 0.14
Neuropathy | CP+P	0.20a	0.10 – 0.40
Neuropathy | CPB+B	0.07a	0.03 – 0.14
Bowel Perforation | CPB+B	0.03a	0.015 – 0.10
Death | Bowel Perforation	0.50a	0.00 – 0.75
Progression Free Survival (months)
CP
Optimal	24a	reference
Suboptimal	14a	reference
CP+P
Optimal	35a	17.5 – 105
Suboptimal	20a	10 – 60
CPB+B
Optimal	35a	17.5 – 105
Suboptimal	20a	10 – 60
Overall Survival (months)
CP
Optimal	48a	reference
Suboptimal	35a	reference
CP+P
Optimal	70a	35 – 210
Suboptimal	42a	21 – 126
CPB+B
Optimal	70a	35 – 210
Suboptimal	42a	21 – 126
Quality of Life Utility Index
Chemotherapy
CP Cycles	0.77a	0.64 – 0.85
CPB Cycles	0.77a	0.64 – 0.85
P Maintenance Cycles	0.80a	0.66 – 0.88
B Maintenance Cycles	0.82a	0.68 – 0.90
Months 1–6 Recovery	0.84a	0.70 – 0.93
PFS	0.85 [34]	0.75 – 1.00
Cancer recurrence	0.65 [34]	0.50 – 0.85
Neuropathy	0.94 [35]	0.80 – 1.00
Bowel perforation	0.85 [36]	0.50 – 0.95
Discount rate	0.03	0.00 – 0.05

^aSee text for rationale

Note. CP: Carboplatin and Paclitaxel; CP+P: Carboplatin and Paclitaxel followed by Paclitaxel consolidation; CPB+B: Carboplatin and Paclitaxel and Bevacizumab followed by Bevacizumab consolidation.